Who Paid My Doc
Jason Rogers
Cardiovascular Disease Sacramento, CA Medical Doctor
NPI 1295717163 CMS profile 239514
4860 Y St, Suite 2820, Sacramento, CA 95817
General payments
$4,375,587
Research payments
$23,266
Ownership & investment interest
$0
Research they led as principal investigator
$687,073
Through program year 2025, Jason Rogers of Sacramento, CA is reported in the CMS Open Payments database as having received $4,375,587 across 540 general payments and $23,266 in research payments paid to them. Separately, studies naming them as principal investigator received $687,073 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $38,812 | 36 | |
| 2024 | General | $147,307 | 72 | |
| 2023 | General | $644,249 | 59 | |
| 2022 | General | $50,792 | 57 | |
| 2021 | General | $117,334 | 84 | |
| 2020 | General | $534,371 | 73 | |
| 2019 | General | $2,842,721 | 159 | |
| 2019 | Research | $23,266 | 8 |
Beside peers
- Jason Rogers
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Jason Rogers were reported at $38,812. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Jason Rogers | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,842,721 | $450 | $127–$1,392 | $163 |
| 2020 | $534,371 | $242 | $77–$751 | $114 |
| 2021 | $117,334 | $335 | $101–$1,037 | $132 |
| 2022 | $50,792 | $395 | $121–$1,211 | $149 |
| 2023 | $644,249 | $443 | $136–$1,283 | $160 |
| 2024 | $147,307 | $450 | $136–$1,323 | $164 |
| 2025 | $38,812 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 29 drugsPart D claims
1,180
Drug cost
$227,874
Branded share of claims
22.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 80 | $109,859 | |
| Jardiance Empagliflozin | Brand | 19 | $23,234 | |
| Xarelto Rivaroxaban | Brand | 22 | $22,142 | |
| Entresto Sacubitril/Valsartan | Brand | 13 | $20,033 | |
| Repatha Sureclick Evolocumab | Brand | 26 | $19,632 | |
| Brilinta Ticagrelor | Brand | 24 | $13,616 | |
| Atorvastatin Calcium | Generic | 169 | $4,145 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 63 | $3,012 | |
| Rosuvastatin Calcium | Generic | 41 | $2,099 | |
| Metoprolol Succinate | Generic | 103 | $2,016 |
The 10 drugs with the highest cost, of 29 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 44 billing codesPaid by Medicare
$64,609
Medicare patients
235
Services billed
611
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 70% | |
| Atrial fibrillation | 60% | |
| Heart failure | 57% | |
| Arthritis | 56% | |
| Chronic kidney disease | 46% | |
| Diabetes | 39% | |
| COPD | 29% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
548 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in California
Ted Love
Cardiovascular Disease · Hillsborough, CA
Paul Kurth
Cardiovascular Disease · Santa Barbara, CA
Matthew Budoff
Cardiovascular Disease · Torrance, CA
Eric Topol
Cardiovascular Disease · La Jolla, CA
Cathleen Bairey-Merz
Cardiovascular Disease · Los Angeles, CA
Gagan Singh
Cardiovascular Disease · Sacramento, CA
Related records
Cardiovascular Disease in California
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.